AbCellera Biologics Inc. (ABCL)
About AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $75.1M
- Net income
- -$146.4M
- Total assets
- $1.4B
- Market cap
- $1.6B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.6B
- Shares outstanding
- 126.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 11, 2020
AbCellera Biologics Inc. (ABCL) Stock Price
- Reported a net loss of $146.4M in FY2025.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AbCellera Biologics Inc..
Write a review
News about AbCellera Biologics Inc.
News & sentiment via Polygon.io
AbCellera Biologics Inc.: frequently asked questions
Is AbCellera Biologics Inc. an American company?
AbCellera Biologics Inc. is a US-based company headquartered in Vancouver, A1, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is AbCellera Biologics Inc. headquartered?
AbCellera Biologics Inc. is headquartered in Vancouver, A1, United States.
Is AbCellera Biologics Inc. publicly traded?
Yes — AbCellera Biologics Inc. is a publicly traded company. Its stock trades under the ticker symbol ABCL on the NASDAQ.
What does AbCellera Biologics Inc. do?
AbCellera Biologics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
